erm1 Antibody

What is ERM-1 and what is its biological function?

ERM-1 is a homolog of the ezrin-radixin-moesin (ERM) family of cytoskeletal linker proteins. It functions to connect the plasma membrane to the actin cytoskeleton, playing a crucial role in maintaining cell shape, membrane organization, and epithelial integrity. In C. elegans, ERM-1 localizes most prominently to the apical membranes in the polarized alimentary tract and is found on the apical cell cortex of many cells during development . As a cytoskeletal linker, ERM-1 is essential for proper epithelial morphogenesis and maintenance of apical-basal polarity in various tissues.

What types of ERM-1 antibodies are available for research applications?

Several types of ERM-1 antibodies have been developed:

The monoclonal antibodies 5G2 and 7G2 have been specifically characterized for C. elegans research, with 5G2 (renamed ERM1) submitted to the Developmental Studies Hybridoma Bank . These antibodies were generated against a His6-tagged fusion protein encompassing amino acids 209-563 of ERM-1. Both monoclonal antibodies recognize a single protein band of 72 kDa on western blots, consistent with the expected size of ERM-1 .

How do monoclonal and polyclonal ERM-1 antibodies compare in research applications?

The relative performance of monoclonal versus polyclonal ERM-1 antibodies varies by application:

What distinguishes ERM-1 from EMR1/ADGRE1 in antibody selection?

Researchers should be aware of potential confusion between ERM-1 and EMR1:

• ERM-1 (ezrin-radixin-moesin family member): A cytoskeletal linker protein studied extensively in C. elegans development

• EMR1/ADGRE1 (EGF-like module containing mucin-like hormone receptor 1): An adhesion G protein-coupled receptor, with ADGRE1 being the human gene

These represent distinct proteins with different functions, structures, and expression patterns. When selecting antibodies, researchers should carefully verify which protein is being targeted, as commercial suppliers may list both under similar search terms . Checking the molecular weight (ERM-1: ~72 kDa; human EMR1/ADGRE1: ~97.7 kDa with 5 isoforms) and sequence epitope information can help confirm the correct target protein .

What is the optimal fixation protocol for immunohistochemistry with ERM-1 antibodies?

The fixation method significantly impacts ERM-1 antibody performance in immunohistochemistry. Research has shown that methanol fixation works effectively for ERM-1 detection in C. elegans whole mounts . A recommended protocol includes:

• Collect worms in M9 buffer

• Fix in ice-cold 100% methanol for 5 minutes at -20°C

• Permeabilize with acetone for 5 minutes at -20°C

• Rehydrate through graded methanol series (90%, 60%, 30%, PBS)

• Block with 1% BSA in PBS-T for 30-60 minutes

• Incubate with primary ERM-1 antibody overnight at 4°C

• Wash extensively with PBS-T

• Incubate with appropriate secondary antibody

• Mount in anti-fade medium

Researchers should note that antibody specificity can be condition-dependent—the same monoclonal can be specific under one fixation condition but not under another . Therefore, optimization might be necessary for specific experimental systems, and results should be validated with appropriate controls.

How can researchers validate the specificity of ERM-1 antibodies in their experimental systems?

Validating antibody specificity is crucial for reliable results. For ERM-1 antibodies, consider these approaches:

• Genetic validation: Test antibody staining in erm-1 knockout or knockdown animals. Complete absence of signal in null mutants provides strong evidence for specificity.

• Peptide competition: Pre-incubate the antibody with excess purified ERM-1 protein or immunogenic peptide before applying to samples. Specific signals should be significantly reduced.

• Comparison with GFP reporters: Compare antibody staining patterns with GFP-ERM-1 fusion protein expression. The monoclonal antibodies 5G2 and 7G2 have been shown to produce staining patterns similar to GFP-ERM-1 reporters .

• Western blot analysis: Verify that the antibody detects a band of the expected size (approximately 72 kDa for ERM-1) .

• Multiple antibody validation: Use different antibodies targeting different epitopes of ERM-1.

These validation steps should be documented as they strengthen the credibility of experimental findings and help address the noted concern that "specificity is condition dependent" .

What are the optimal dilutions and incubation conditions for different ERM-1 antibody applications?

Optimal conditions vary by application and specific antibody. Based on research practices with ERM-1 antibodies:

For the monoclonal antibodies 5G2 and 7G2, higher concentrations are typically needed for immunohistochemistry compared to western blotting . Researchers should perform a dilution series to determine optimal conditions for their specific experimental system, as performance can vary between antibody lots and experimental conditions.

What sample preparation techniques maximize ERM-1 detection in western blotting?

For optimal detection of ERM-1 by western blotting, preparation techniques should preserve protein integrity while ensuring effective extraction. A recommended protocol includes:

• Harvest and wash worms/tissues in cold buffer

• Homogenize in appropriate lysis buffer containing protease inhibitors

• Sonicate briefly to disrupt tissues

• Centrifuge at 14,000g for 15 minutes at 4°C to remove debris

• Determine protein concentration

• Add reducing sample buffer and heat at 95°C for 5 minutes

• Load 20-50 μg of total protein per lane

Both 5G2 and 7G2 monoclonal antibodies have been documented to recognize a single protein band of approximately 72 kDa on western blots of C. elegans lysates . Occasionally, the 7G2 antibody detected an additional 10 kDa band, making 5G2 (renamed ERM1) the preferred choice for western blot applications .

How can ERM-1 antibodies be used to study cell polarity in developmental contexts?

ERM-1 antibodies provide valuable tools for investigating epithelial cell polarity:

• Developmental time course analysis: Track ERM-1 localization across embryonic and larval stages to monitor establishment of apical-basal polarity. During C. elegans development, ERM-1 progressively restricts from broad cortical distribution to the apical membrane domains .

• Multi-marker polarity analysis: Combine ERM-1 immunostaining with markers for junctional proteins (e.g., DLG-1, HMR-1) and basolateral proteins (e.g., LET-413) to comprehensively map epithelial domain organization .

• Polarity perturbation studies: Assess how genetic or pharmacological disruption of polarity pathways affects ERM-1 distribution. Changes in ERM-1 localization serve as readouts for defects in apical domain specification.

• Morphogenetic event analysis: Examine ERM-1 during tubulogenesis, lumen formation, and epithelial remodeling to understand cytoskeletal contributions to tissue architecture.

• Quantitative domain mapping: Measure apical domain size and morphology using ERM-1 as a marker, providing quantitative phenotypes for genetic studies.

The 5G2 and 7G2 monoclonal antibodies have been validated for these applications, showing specific labeling of the apical cortex of the pharyngeal-intestinal tract and hypodermal cells in C. elegans .

What approaches enable simultaneous detection of ERM-1 with other cellular markers?

Multiple strategies can be employed for multi-protein detection:

• Sequential immunostaining: Apply primary antibodies sequentially when using antibodies from the same species. This approach can be enhanced with specialized blocking steps between antibody applications.

• Multi-species primary antibodies: Combine mouse anti-ERM-1 (5G2 or 7G2) with antibodies raised in different species (rabbit, goat, etc.) for simultaneous staining, followed by species-specific secondary antibodies with distinct fluorophores .

• Combining antibodies with fluorescent proteins: In transgenic lines expressing fluorescent markers, use ERM-1 immunostaining to examine relationships with other labeled structures. This approach has been validated with ERM-1 antibodies in GFP-reporter strains .

• Specialized detection systems: Use Zenon labeling technology or directly conjugated primary antibodies to overcome species limitations.

• Sequential imaging with spectral unmixing: Apply computational approaches to separate overlapping fluorophore signals in multicolor imaging.

When designing multi-labeling experiments, researchers should optimize antibody concentrations to achieve balanced signal intensities across different channels.

How do mutations in erm-1 affect antibody binding and experimental interpretation?

Mutations in erm-1 can impact antibody binding in several ways:

• Epitope disruption: Mutations within the antibody epitope region (amino acids 209-563 for 5G2 and 7G2) may directly prevent antibody binding even if protein is expressed .

• Protein instability: Some mutations may reduce ERM-1 protein levels through decreased stability, resulting in weaker immunostaining that could be misinterpreted.

• Conformational changes: Mutations can alter protein folding, potentially masking epitopes that are accessible in the wild-type protein.

• Truncated proteins: Nonsense mutations producing truncated proteins may or may not be detected depending on whether the epitope region is retained.

For rigorous interpretation of mutant phenotypes, researchers should:

• Use multiple antibodies targeting different epitopes when possible

• Combine immunostaining with western blot analysis to assess protein levels and size

• Include appropriate controls, including known null mutants if viable

• Consider the specific location of mutations relative to antibody epitopes

The complexity of interpreting antibody staining in mutant backgrounds is acknowledged in the ERM-1 antibody characterization literature, noting that "significant experimental effort would have been required to develop or characterize the reagents needed to enable us to document the specificity of the monoclonal lines" .

What are common sources of background or non-specific binding with ERM-1 antibodies?

Several factors can contribute to background signal when using ERM-1 antibodies:

• Cross-reactivity with related proteins: ERM-1 belongs to a conserved protein family, and antibodies may cross-react with other ERM family members.

• Fixation artifacts: Certain fixation methods can create epitopes that are artifactually recognized by antibodies. Specificity has been noted to be condition-dependent for ERM-1 monoclonals .

• Secondary antibody background: Non-specific binding of secondary antibodies, particularly in tissues with endogenous Fc receptors.

• Autofluorescence: Natural fluorescence from tissues, particularly intestine, can be misinterpreted as specific signal.

• Tag-specific reactivity: As observed with the 2H11 and 5E2 monoclonals that reacted to the His6-tag rather than ERM-1 itself .

To minimize these issues:

• Include appropriate negative controls (secondary-only, isotype controls)

• Use blocking reagents to reduce non-specific binding

• Consider spectral imaging to distinguish autofluorescence from specific signal

• Optimize fixation and permeabilization conditions

• Validate results with genetic approaches when possible

The 5G2 monoclonal (renamed ERM1) was identified as the preferred antibody for C. elegans research partly due to its lower background compared to 7G2, which occasionally detected an additional 10 kDa band on western blots .

How should researchers interpret different subcellular localization patterns of ERM-1?

ERM-1 localization patterns provide insights into cell polarity and membrane organization:

• Normal apical localization: In wild-type C. elegans, ERM-1 typically localizes to:

  • Apical cortex of the pharyngeal-intestinal tract

  • Apical domains of hypodermal cells

  • Cell cortex of contacting membranes in early embryonic stages

• Cortical vs. cytoplasmic distribution: ERM proteins cycle between active membrane-bound and inactive cytoplasmic forms, so shifts between these pools may indicate changes in activation state.

• Developmental transitions: ERM-1 naturally redistributes during development, with initially broad distribution becoming restricted to apical domains during epithelial polarization .

• Altered patterns in experimental conditions: Changes in ERM-1 distribution can indicate:

  • Disrupted apical-basal polarity

  • Cytoskeletal reorganization

  • Membrane domain remodeling

  • Protein misfolding or aggregation

Interpretation is enhanced by examining co-localization with markers for junctions (DLG-1, HMR-1), basolateral domains (LET-413), and the actin cytoskeleton . Researchers should quantify distribution patterns across multiple samples and consider developmental context when interpreting localization data.

What quantitative methods can be used to analyze ERM-1 immunostaining data?

Rigorous quantitative analysis enhances the value of ERM-1 immunostaining:

• Fluorescence intensity measurements:

  • Calculate apical-to-cytoplasmic intensity ratios

  • Measure absolute intensity at specific membrane domains

  • Compare intensity across different tissues or developmental stages

• Spatial distribution analysis:

  • Generate line scans across cellular domains

  • Create heat maps of protein distribution

  • Measure the width or area of ERM-1-positive domains

• Colocalization quantification:

  • Calculate Pearson's or Manders' coefficients with other markers

  • Assess spatial relationships between ERM-1 and junctional proteins

Statistical approaches should include appropriate controls and sufficient biological replicates (typically n≥15 animals) to account for natural variation. These quantitative measures provide objective criteria for phenotypic assessment in genetic or pharmacological studies.

How does ERM-1 expression and localization change throughout C. elegans development?

ERM-1 exhibits dynamic patterns throughout development:

• Early embryogenesis:

  • Initially detected at cell-cell contacts

  • Distributed broadly at the cell cortex of most cells

  • Not yet restricted to apical domains

• Mid-embryogenesis:

  • Progressive restriction to apical domains in developing epithelia

  • Enrichment at nascent apical surfaces of intestinal precursors

  • Coincides with establishment of apicobasal polarity

• Late embryogenesis:

  • Highly enriched at the apical brush border of intestinal cells

  • Present at the pharyngeal lumen

  • Detectable in hypodermal cells at apical surfaces

• Larval stages and adults:

  • Maintained at apical surfaces of differentiated epithelia

  • Particularly strong in intestine and pharynx

This developmental sequence provides an important framework for interpreting experimental phenotypes, as disruptions to the normal progression may indicate defects in epithelial polarization or maintenance. The monoclonal antibodies 5G2 and 7G2 have been validated for detecting ERM-1 across these developmental stages .

How can researchers distinguish between true changes in ERM-1 biology and technical artifacts?

Distinguishing biological changes from technical artifacts requires systematic controls:

• Biological controls:

  • Compare wild-type and mutant animals processed in parallel

  • Examine multiple developmental stages to identify stage-specific changes

  • Analyze multiple tissues to distinguish tissue-specific versus global effects

• Technical controls:

  • Include secondary-antibody-only samples to assess background

  • Process samples with competing peptide to verify specificity

  • Compare multiple fixation methods to identify fixation artifacts

  • Use multiple antibodies targeting different ERM-1 epitopes

• Validation approaches:

  • Correlate antibody staining with GFP-ERM-1 reporter patterns

  • Confirm protein expression changes by western blotting

  • Use RNAi or genetic approaches to verify phenotypes

  • Apply super-resolution microscopy to resolve ambiguous localization patterns

Researchers should be particularly cautious about interpreting subtle changes in localization patterns. The developers of ERM-1 monoclonal antibodies noted that "specificity is condition dependent" and that a monoclonal "can be specific on whole mounts under one fixation condition, but not under another" .